Form 10-Q for PRAXSYN CORP
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Statements Regarding Forward-Looking Statements
This Management's Discussion and Analysis of Financial Condition and Results Of Operation and other parts of this Form 10-Q contain forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this Form 10-Q are based on information available to us on the date hereof, and except as required by law, we assume no obligation to update any such forward-looking statements. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth in the current report on the Form 8-K/A as filed with the Securities and Exchange Commission on July 16, 2014 and other filings with the SEC. The following should be read in conjunction with our condensed consolidated financial statements contained elsewhere in this report
Dollar amounts of $1.0 million or more are rounded to the nearest one tenth of a million; all other dollar amounts are rounded to the nearest one thousand and all percentages are stated to the nearest one tenth of one percent.
Form 8-K/A for PRAXSYN CORP
Completion of Acquisition or Disposition of Assets, Financial Statements and Exhib
Item 2.01 Completion of Acquisition or Disposition of Assets.
On March 31, 2014, Praxsyn closed an Agreement and Plan of Merger Agreement (the "APMA") with Pharmacy Development Corp., a California corporation ("PDC") whereby the Company acquired PDC through a forward triangular merger into the Company's wholly owned subsidiary PDC, Inc., a Nevada corporation in exchange for five hundred thousand (500,000) shares of the Company's Series D Convertible Preferred Stock (the "Series D Stock").
IRVINE, Calif., June 23, 2014 -- Praxsyn Corporation (OTCQB:PXYN), a medication and service provider for medical practitioners, announced that it is making progress in filing its Form 10-Q for the quarter ended March 31, 2014.
"The work on the first quarter 10-Q continues and is meeting our internal completion deadlines," said Dan O'Brien, CFO, Praxsyn Corporation. "Our continued work requires the accounting team to conduct detailed research and confirm many historical facts and figures for several entities' most important accounts throughout the years 2012 and 2013, as well as the first quarter of 2014, which will then be submitted to our auditor. Based upon our ability to continue to complete this work and assuming continued progress at a similar rate, we hope to have all material information required for the 10-Q filing to our auditor by June 27, 2014."
- Appoints Interim CEO and CFO
- Update on Timing of Form 10-Q Filing
- Updated Company Address
IRVINE, Calif., June 4, 2014 -- Praxsyn Corporation (OTCQB:PAWS), a medication and service provider for medical practitioners, announced that Edward F. Kurtz, 51, has been elected to serve as the Company's Chief Operating Officer, which was effective on May 3, 2014. He was also appointed as Interim CEO, President and Chairman of the Board. Kurtz has more than 25 years of leadership experience in business development and operations, most recently in the strategic planning and growth of Mesa Pharmacy, a custom compounding pharmacy specializing in pain relief.
Delay Caused by Complexity Due to Merging 2 Companies
PALO ALTO, Calif., May 19, 2014 -- The PAWS Pet Company, Inc. (OTCQB:PAWS), announces that its First Quarter 10Q filing will not be filed on time due to the complexity and extreme amount accounting work required by its recent merger.